Interface
TILE · NASDAQ
Key indicators
TILE profitability and balance sheet ratios
EPS $0.8818 in Q2 FY26, up 60.0% on a year earlier.
| Period | EPS |
|---|---|
| Q4 FY24 | $0.3675 |
| Q1 FY25 | $0.2197 |
| Q2 FY25 | $0.5512 |
| Q3 FY25 | $0.7804 |
| Q4 FY25 | $0.4195 |
| Q1 FY26 | $1.99 |
| May 2026 | $0.4001 |
| Q2 FY26 | $0.8818 |
Where the money went
Q2 FY26, from revenue to net income
Interface brought in $395.7M of revenue in Q2 FY26, +5.4% on a year earlier. 13¢ of every dollar became profit.
- Revenue
- $395.7M
- Costs, expenses and taxes
- $344.3M
- Net income
- $51.4M
- Net margin
- 13.0%
Income statement
Revenue and profit by reporting period
| Line item | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|
| Revenue | $349.4M | $331.0M | $395.7M |
| Gross profit | $134.8M | $126.7M | $178.1M |
| Operating income | $35.4M | $32.3M | $74.9M |
| Net income | $24.4M | $23.6M | $51.4M |
| Diluted EPS | $0.41 | $0.40 | $0.88 |
Balance sheet
What the company owns and owes at period end
| Line item | Dec 2025 | May 2026 | Jul 2026 |
|---|---|---|---|
| Total assets | $1.2B | $1.2B | $1.3B |
| Total liabilities | $0.6B | $0.6B | $0.6B |
| Shareholder equity | $0.6B | $0.6B | $0.7B |
| Cash and short-term investments | $0.1B | $0.1B | $0.1B |
| Total debt | $0.2B | $0.2B | $0.2B |
Cash flow
Cash in and out from operations, investing and financing
| Line item | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|
| Operating cash flow | $49.3M | $13.5M | $38.4M |
| Investing cash flow | −$20.7M | −$10.3M | −$12.2M |
| Financing cash flow | −$145.3M | −$12.4M | −$5.5M |
| Capital expenditure | −$20.7M | −$10.3M | −$12.2M |
| Free cash flow | $28.6M | $3.2M | $26.2M |
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.